NYSE:ZTS - Zoetis Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$90.26 +0.61 (+0.68 %)
(As of 09/25/2018 04:00 PM ET)
Previous Close$89.65
Today's Range$90.13 - $90.87
52-Week Range$62.79 - $93.67
Volume1.75 million shs
Average Volume2.56 million shs
Market Capitalization$43.28 billion
P/E Ratio37.76
Dividend Yield0.56%
Beta1.02
Zoetis logoZoetis Inc. discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, which comprise allergy and dermatology, pain and sedation, antiemetic, reproductive, and oncology products. In addition, the company offers other product categories, including nutritionals and agribusiness services, as well as products and services in complementary areas, such as biodevices, diagnostics, and genetics. It markets its products to veterinarians, livestock producers, and people who raise and care for farm and companion animals through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Receive ZTS News and Ratings via Email

Sign-up to receive the latest news and ratings for ZTS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:ZTS
CUSIP98978V10
Phone973-822-7000

Debt

Debt-to-Equity Ratio2.50
Current Ratio4.38
Quick Ratio2.92

Price-To-Earnings

Trailing P/E Ratio37.76
Forward P/E Ratio29.40
P/E Growth1.7

Sales & Book Value

Annual Sales$5.31 billion
Price / Sales8.19
Cash Flow$2.9429 per share
Price / Cash30.67
Book Value$3.67 per share
Price / Book24.59

Profitability

EPS (Most Recent Fiscal Year)$2.40
Net Income$864 million
Net Margins19.95%
Return on Equity72.30%
Return on Assets15.96%

Miscellaneous

Employees9,200
Outstanding Shares481,820,000
Market Cap$43.28 billion

Zoetis (NYSE:ZTS) Frequently Asked Questions

What is Zoetis' stock symbol?

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis announced a quarterly dividend on Tuesday, May 15th. Shareholders of record on Friday, July 20th will be given a dividend of $0.126 per share on Tuesday, September 4th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.56%. The ex-dividend date is Thursday, July 19th. View Zoetis' Dividend History.

How were Zoetis' earnings last quarter?

Zoetis Inc (NYSE:ZTS) issued its earnings results on Thursday, August, 2nd. The company reported $0.77 EPS for the quarter, beating analysts' consensus estimates of $0.71 by $0.06. The firm earned $1.42 billion during the quarter, compared to the consensus estimate of $1.38 billion. Zoetis had a return on equity of 72.30% and a net margin of 19.95%. The firm's revenue for the quarter was up 11.5% on a year-over-year basis. During the same period last year, the firm earned $0.53 EPS. View Zoetis' Earnings History.

When is Zoetis' next earnings date?

Zoetis is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for Zoetis.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis issued an update on its FY18 earnings guidance on Thursday, August, 2nd. The company provided earnings per share guidance of $3.00-3.10 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.05. The company issued revenue guidance of $5.7-5.8 billion, compared to the consensus revenue estimate of $5.74 billion.

What price target have analysts set for ZTS?

16 brokerages have issued twelve-month price targets for Zoetis' stock. Their forecasts range from $77.00 to $103.00. On average, they anticipate Zoetis' stock price to reach $91.0714 in the next year. This suggests a possible upside of 0.9% from the stock's current price. View Analyst Price Targets for Zoetis.

What is the consensus analysts' recommendation for Zoetis?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 7 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zoetis.

What are Wall Street analysts saying about Zoetis stock?

Here are some recent quotes from research analysts about Zoetis stock:
  • 1. According to Zacks Investment Research, "Zoetis’ companion animal business continues to perform well on higher international sales of Apoquel and Simparica.  Growth from new parasiticide products, vaccines and strong dermatology portfolio has also boosted the top-line. The Abaxis acquisition of will further strengthen the company’s presence in the animal health diagnostics market, a fast-growing portion of the animal health industry which should further boost sales. Moreover, Zoetis five-year collaboration agreement with Regeneron to research the use of latter’s monoclonal antibody therapeutics in animals and discover new veterinary treatments will further diversify the broad portfolio. Shares of Zoetis have outperformed the industry in the year so far. However, Zoetis faces stiff competition from companies like Merck Animal Health. Disease outbreak among animals is a material cause of concern for Zoetis’ livestock products." (9/10/2018)
  • 2. Cantor Fitzgerald analysts commented, "We rate ZTS as 12-month price target of $98. Given the company’s durable business model and the positive outlook for macro factors, we think the multiple will hold and upwards earnings revisions should drive shares higher. Valuation Summary We use a blend of DCF and multiples analysis (EV/EBITDA) to get to our 12- month price target of $98." (5/16/2018)

Who are some of Zoetis' key competitors?

Who are Zoetis' key executives?

Zoetis' management team includes the folowing people:
  • Mr. Juan Ramón Alaix, CEO & Director (Age 67)
  • Mr. Glenn C. David, Exec. VP & CFO (Age 46)
  • Dr. Catherine A. Knupp, Exec. VP and Pres of R&D (Age 57)
  • Mr. Clinton A. Lewis Jr., EVP and Pres of International Ops., Commercial Devel., Global Genetics & Aquatic Health (Age 51)
  • Ms. Kristin C. Peck, Exec. VP and Group Pres of U.S. Operations, Bus. Devel. & Strategy (Age 47)

Who are Zoetis' major shareholders?

Zoetis' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.71%), Morgan Stanley (3.07%), Polen Capital Management LLC (1.93%), Massachusetts Financial Services Co. MA (1.57%), Brown Advisory Inc. (1.37%) and Wells Fargo & Company MN (1.32%). Company insiders that own Zoetis stock include Catherine A Knupp, Glenn David, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Roman Trawicki and Roxanne Lagano. View Institutional Ownership Trends for Zoetis.

Which institutional investors are selling Zoetis stock?

ZTS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Voya Investment Management LLC, American Century Companies Inc., Millennium Management LLC, Jennison Associates LLC, Morgan Stanley, Brown Advisory Inc. and Waddell & Reed Financial Inc.. Company insiders that have sold Zoetis company stock in the last year include Catherine A Knupp, Glenn David, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Roman Trawicki and Roxanne Lagano. View Insider Buying and Selling for Zoetis.

Which institutional investors are buying Zoetis stock?

ZTS stock was bought by a variety of institutional investors in the last quarter, including Banque Pictet & Cie SA, Janus Henderson Group PLC, Bank of Montreal Can, New York State Teachers Retirement System, Marshall Wace LLP, Wells Fargo & Company MN, Bank of New York Mellon Corp and Bank of New York Mellon Corp. View Insider Buying and Selling for Zoetis.

How do I buy shares of Zoetis?

Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zoetis' stock price today?

One share of ZTS stock can currently be purchased for approximately $90.27.

How big of a company is Zoetis?

Zoetis has a market capitalization of $43.28 billion and generates $5.31 billion in revenue each year. The company earns $864 million in net income (profit) each year or $2.40 on an earnings per share basis. Zoetis employs 9,200 workers across the globe.

What is Zoetis' official website?

The official website for Zoetis is http://www.zoetis.com.

How can I contact Zoetis?

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]


MarketBeat Community Rating for Zoetis (NYSE ZTS)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  568 (Vote Outperform)
Underperform Votes:  349 (Vote Underperform)
Total Votes:  917
MarketBeat's community ratings are surveys of what our community members think about Zoetis and other stocks. Vote "Outperform" if you believe ZTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/25/2018 by MarketBeat.com Staff

Featured Article: Ex-Dividend

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel